Katsuaki Maehara

Katsuaki Maehara: The changes in TME and TKI treatment resistance by EGFR and ALK TKI

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X:             .

“A valuable paper that reveals the changes in tumor microenvironment (TME) and Tyrosine Kinase Inhibitor (TKI) treatment resistance by EGFR and ALK TKI, and studies on overcoming resistance with adjuvant therapies such as aspirin.”

Katsuaki Maehara: The changes in TME and TKI treatment resistance by EGFR and ALK TKI

Proceed to the paper.
Source: Katsuaki Maehara/X

Adjuvant Therapy ALK TKI Aspirin cancer EGFR Katsuaki Maehara Medical Education Colleagues OncoDaily Oncology TKI TME tumor microenvironment